
The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial
Publication
, Journal Article
Eriksen, EF; Lyles, KW; Colon-Emeric, CS; Pieper, CF; Magaziner, JS; Adachi, JD; Hyldstrup, L; Recknor, C; Nordsletten, L; Lavecchia, C; Hu, H ...
Published in: CALCIFIED TISSUE INTERNATIONAL
January 1, 2008
Duke Scholars
Published In
CALCIFIED TISSUE INTERNATIONAL
ISSN
0171-967X
Publication Date
January 1, 2008
Volume
82
Start / End Page
S41 / S41
Publisher
SPRINGER
Related Subject Headings
- Endocrinology & Metabolism
- 4003 Biomedical engineering
- 3202 Clinical sciences
- 1103 Clinical Sciences
- 0903 Biomedical Engineering
- 0601 Biochemistry and Cell Biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Eriksen, E. F., Lyles, K. W., Colon-Emeric, C. S., Pieper, C. F., Magaziner, J. S., Adachi, J. D., … Mesenbrink, P. (2008). The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial. CALCIFIED TISSUE INTERNATIONAL, 82, S41–S41.
Eriksen, E. F., K. W. Lyles, C. S. Colon-Emeric, C. F. Pieper, J. S. Magaziner, J. D. Adachi, L. Hyldstrup, et al. “The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial.” CALCIFIED TISSUE INTERNATIONAL 82 (January 1, 2008): S41–S41.
Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, et al. The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial. CALCIFIED TISSUE INTERNATIONAL. 2008 Jan 1;82:S41–S41.
Eriksen, E. F., et al. “The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial.” CALCIFIED TISSUE INTERNATIONAL, vol. 82, SPRINGER, Jan. 2008, pp. S41–S41.
Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P. The timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: Results from horizon-recurrent fracture trial. CALCIFIED TISSUE INTERNATIONAL. SPRINGER; 2008 Jan 1;82:S41–S41.

Published In
CALCIFIED TISSUE INTERNATIONAL
ISSN
0171-967X
Publication Date
January 1, 2008
Volume
82
Start / End Page
S41 / S41
Publisher
SPRINGER
Related Subject Headings
- Endocrinology & Metabolism
- 4003 Biomedical engineering
- 3202 Clinical sciences
- 1103 Clinical Sciences
- 0903 Biomedical Engineering
- 0601 Biochemistry and Cell Biology